Harvard Bioscience, Inc. (HBIO) Financials

HBIO Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 76.3 million 68.9 million
March 31, 2026 77.9 million 67.9 million
Dec. 31, 2025 80.1 million 66.3 million
Sept. 30, 2025 78.0 million 63.9 million

HBIO Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -365000 380000
March 31, 2026 -1.1 million 257000
Dec. 31, 2025 -695000 459000
Sept. 30, 2025 736000 324000

HBIO Net Income

No data available :(

HBIO Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 6.5 million 36.7 million 7.5 million
March 31, 2026 7.1 million 36.2 million 6.4 million
Dec. 31, 2025 8.6 million 35.9 million 6.9 million
Sept. 30, 2025 6.8 million - 7.3 million

HBIO Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 4.5 million
March 31, 2026 4.5 million
Dec. 31, 2025 4.4 million
Sept. 30, 2025 4.5 million

HBIO Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 688000 2.5 million 10.0 million 5.4 million
March 31, 2026 426000 2.3 million 10.0 million 5.3 million
Dec. 31, 2025 599000 2.2 million 9.2 million 5.1 million
Sept. 30, 2025 348000 2.1 million 8.8 million 4.6 million

HBIO Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 22.7 million 10.1 million
March 31, 2026 20.8 million 8.5 million
Dec. 31, 2025 23.7 million 9.6 million
Sept. 30, 2025 20.6 million 8.6 million

HBIO Revenue by Segment
Graph available only for paid members. Upgrade to see it.

HBIO

Price: $8.09

52 week price:
3.76
9.40

Payout Ratio Range:
-26.46%
-0.80%

Earnings Per Share: -2.23 USD

Exchange: NGM

Sector: Healthcare

Industry: Medical Instruments & Supplies

Country: United States

Volume: 13674

Ebitda: 836000

Market Capitalization: 38.6 million

Links: